Targeting New Pathways in Alopecia Areata: The Role of JAK Inhibitors(ID: i818a) Survey

Question Title

* 2. How many patients with AA do you manage per week? 

1 to 10

11 to 25

26 to 50

I am not directly involved in patient care

Question Title

* 3. Please select the option that best describes your practice setting.

Academic medical center

Community hospital or medical center

VA, DOD, or other government

Managed care

Research

Pharmaceutical industry

Question Title

* 4. After participating in this activity, how confident are you identifying patients with AA in your practice?

Very confident

Confident

Neutral

Little confidence

No confidence

Question Title

* 5. After participating in this activity, how confident are you treating patients with AA in your practice?

Very confident

Confident

Neutral

Little confidence

No confidence

Question Title

* 6. How committed are you to making changes in your practice based on your participation in this activity?

Very committed

Committed

Neutral

Not committed

I do not plan to make changes

If not committed or do not plan to make changes, please indicate reason

Question Title

* 7. After participating in this activity, which of the following domains do you plan to assess in patients with AA in your practice? Please select all that apply.

Physical signs/symptoms (scalp, skin, nail, hair, irritation, etc)

Emotional impacts

Psychological impacts

Relationship impacts

Social/lifestyle impacts

Question Title

* 8. Which of the following best describes the impact of this activity on your performance?

I gained new strategies/skills/information I can apply to my area of practice

I need more information before I can change my practice

My practice is already consistent with the information presented

This activity will not change my practice

Question Title

* 9. Which new strategies/skills/information will you apply to your area of practice? Please select all that apply.

Improved knowledge of AA pathophysiology and epidemiology

Better ability to empathize with patients due to increased understanding of the burden on patients with AA

Increased use of diagnostic criteria in order to more accurately diagnose patients with AA

Improved ability to individualize patient management according to consensus recommendations

Better able to recognize patients in need of systemic therapy

Greater understanding of current and emerging therapies and their pathophysiology

Making a more informed decision when deciding on treatment

Question Title

* 10. What barriers do you see to making changes in your practice? Please select all that apply.

Lack of knowledge regarding evidence-based strategies

Lack of convincing evidence to warrant change

Lack of time/resources to consider change

Insurance, reimbursement or legal issues

Conflicting guidelines or evidence

Patient compliance and/or patient resource barriers

Other (please explain)

Question Title

* 11. Please rate your level of agreement by checking the appropriate rating.

After participating in today’s activity, I am now better able to:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Discuss the epidemiology of AA and the impact of this disease on patient QOL	Discuss the epidemiology of AA and the impact of this disease on patient QOL Strongly agree	Discuss the epidemiology of AA and the impact of this disease on patient QOL Agree	Discuss the epidemiology of AA and the impact of this disease on patient QOL Neutral	Discuss the epidemiology of AA and the impact of this disease on patient QOL Disagree	Discuss the epidemiology of AA and the impact of this disease on patient QOL Strongly disagree
Understand the clinical manifestations of AA to improve evaluation of disease severity	Understand the clinical manifestations of AA to improve evaluation of disease severity Strongly agree	Understand the clinical manifestations of AA to improve evaluation of disease severity Agree	Understand the clinical manifestations of AA to improve evaluation of disease severity Neutral	Understand the clinical manifestations of AA to improve evaluation of disease severity Disagree	Understand the clinical manifestations of AA to improve evaluation of disease severity Strongly disagree
Employ strategies to individualize treatment for patients with AA	Employ strategies to individualize treatment for patients with AA Strongly agree	Employ strategies to individualize treatment for patients with AA Agree	Employ strategies to individualize treatment for patients with AA Neutral	Employ strategies to individualize treatment for patients with AA Disagree	Employ strategies to individualize treatment for patients with AA Strongly disagree
Summarize the pathophysiology of AA	Summarize the pathophysiology of AA Strongly agree	Summarize the pathophysiology of AA Agree	Summarize the pathophysiology of AA Neutral	Summarize the pathophysiology of AA Disagree	Summarize the pathophysiology of AA Strongly disagree
Discuss emerging therapies for AA, including JAK inhibitors, JAK/TEC inhibitors, and clinical trial data	Discuss emerging therapies for AA, including JAK inhibitors, JAK/TEC inhibitors, and clinical trial data Strongly agree	Discuss emerging therapies for AA, including JAK inhibitors, JAK/TEC inhibitors, and clinical trial data Agree	Discuss emerging therapies for AA, including JAK inhibitors, JAK/TEC inhibitors, and clinical trial data Neutral	Discuss emerging therapies for AA, including JAK inhibitors, JAK/TEC inhibitors, and clinical trial data Disagree	Discuss emerging therapies for AA, including JAK inhibitors, JAK/TEC inhibitors, and clinical trial data Strongly disagree

Question Title

* 12. Please rate your level of agreement by checking the appropriate rating.

Brett King, MD, PhD, effectively:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Presented the Material	Presented the Material Strongly agree	Presented the Material Agree	Presented the Material Neutral	Presented the Material Disagree	Presented the Material Strongly disagree
Avoided Commercial Bias	Avoided Commercial Bias Strongly agree	Avoided Commercial Bias Agree	Avoided Commercial Bias Neutral	Avoided Commercial Bias Disagree	Avoided Commercial Bias Strongly disagree

Question Title

* 13. Please rate your level of agreement by checking the appropriate rating.

Brittany Craiglow, MD, effectively:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Presented the material	Presented the material Strongly agree	Presented the material Agree	Presented the material Neutral	Presented the material Disagree	Presented the material Strongly disagree
Avoided commercial bias	Avoided commercial bias Strongly agree	Avoided commercial bias Agree	Avoided commercial bias Neutral	Avoided commercial bias Disagree	Avoided commercial bias Strongly disagree

Question Title

* 14. Please rate your level of agreement by checking the appropriate rating.

Sergio Vañó Galván, MD, PhD, effectively:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Presented the material	Presented the material Strongly agree	Presented the material Agree	Presented the material Neutral	Presented the material Disagree	Presented the material Strongly disagree
Avoided commercial bias	Avoided commercial bias Strongly agree	Avoided commercial bias Agree	Avoided commercial bias Neutral	Avoided commercial bias Disagree	Avoided commercial bias Strongly disagree

Question Title

* 15. Please rate your level of agreement by checking the appropriate rating.

The content presented:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Enhanced my current knowledge base	Enhanced my current knowledge base Strongly agree	Enhanced my current knowledge base Agree	Enhanced my current knowledge base Neutral	Enhanced my current knowledge base Disagree	Enhanced my current knowledge base Strongly disagree
Addressed my most pressing questions	Addressed my most pressing questions Strongly agree	Addressed my most pressing questions Agree	Addressed my most pressing questions Neutral	Addressed my most pressing questions Disagree	Addressed my most pressing questions Strongly disagree
Promoted improvements or quality in health care	Promoted improvements or quality in health care Strongly agree	Promoted improvements or quality in health care Agree	Promoted improvements or quality in health care Neutral	Promoted improvements or quality in health care Disagree	Promoted improvements or quality in health care Strongly disagree
Was scientifically rigorous and evidence based	Was scientifically rigorous and evidence based Strongly agree	Was scientifically rigorous and evidence based Agree	Was scientifically rigorous and evidence based Neutral	Was scientifically rigorous and evidence based Disagree	Was scientifically rigorous and evidence based Strongly disagree
Avoided commercial bias or influence	Avoided commercial bias or influence Strongly agree	Avoided commercial bias or influence Agree	Avoided commercial bias or influence Neutral	Avoided commercial bias or influence Disagree	Avoided commercial bias or influence Strongly disagree

Targeting New Pathways in Alopecia Areata: The Role of JAK Inhibitors(ID: i818a)

Question Title

* 1. How many years have you been in practice?

Question Title

* 2. How many patients with AA do you manage per week?

Question Title

* 3. Please select the option that best describes your practice setting.

Question Title

* 4. After participating in this activity, how confident are you identifying patients with AA in your practice?

Question Title

* 5. After participating in this activity, how confident are you treating patients with AA in your practice?

Question Title

* 6. How committed are you to making changes in your practice based on your participation in this activity?

Question Title

* 7. After participating in this activity, which of the following domains do you plan to assess in patients with AA in your practice? Please select all that apply.

Question Title

* 8. Which of the following best describes the impact of this activity on your performance?

Question Title

* 9. Which new strategies/skills/information will you apply to your area of practice? Please select all that apply.

Question Title

* 10. What barriers do you see to making changes in your practice? Please select all that apply.

Question Title

* 11. Please rate your level of agreement by checking the appropriate rating.

After participating in today’s activity, I am now better able to:

Question Title

* 12. Please rate your level of agreement by checking the appropriate rating.

Brett King, MD, PhD, effectively:

Question Title

* 13. Please rate your level of agreement by checking the appropriate rating.

Brittany Craiglow, MD, effectively:

Question Title

* 14. Please rate your level of agreement by checking the appropriate rating.

Sergio Vañó Galván, MD, PhD, effectively:

Question Title

* 15. Please rate your level of agreement by checking the appropriate rating.

The content presented:

Question Title

* 16. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

Question Title

* 17. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities on AA:

Question Title

* 18. If you indicated that you perceived commercial bias or influence, please describe:

Question Title

* 1. How many years have you been in practice?

Question Title

* 2. How many patients with AA do you manage per week?

Question Title

* 3. Please select the option that best describes your practice setting.

Question Title

* 4. After participating in this activity, how confident are you identifying patients with AA in your practice?

Question Title

* 5. After participating in this activity, how confident are you treating patients with AA in your practice?

Question Title

* 6. How committed are you to making changes in your practice based on your participation in this activity?

Question Title

* 7. After participating in this activity, which of the following domains do you plan to assess in patients with AA in your practice? Please select all that apply.

Question Title

* 8. Which of the following best describes the impact of this activity on your performance?

Question Title

* 9. Which new strategies/skills/information will you apply to your area of practice? Please select all that apply.

Question Title

* 10. What barriers do you see to making changes in your practice? Please select all that apply.

Question Title

* 11. Please rate your level of agreement by checking the appropriate rating. After participating in today’s activity, I am now better able to:

Question Title

* 12. Please rate your level of agreement by checking the appropriate rating. Brett King, MD, PhD, effectively:

Question Title

* 13. Please rate your level of agreement by checking the appropriate rating. Brittany Craiglow, MD​, effectively:

Question Title

* 14. Please rate your level of agreement by checking the appropriate rating. Sergio Vañó Galván, MD, PhD​, effectively:

Question Title

* 15. Please rate your level of agreement by checking the appropriate rating. The content presented:

Question Title

* 16. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

Question Title

* 17. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities on AA:

Question Title

* 18. If you indicated that you perceived commercial bias or influence, please describe:

* 2. How many patients with AA do you manage per week? 

* 11. Please rate your level of agreement by checking the appropriate rating.

After participating in today’s activity, I am now better able to:

* 12. Please rate your level of agreement by checking the appropriate rating.

Brett King, MD, PhD, effectively:

* 13. Please rate your level of agreement by checking the appropriate rating.

Brittany Craiglow, MD, effectively:

* 14. Please rate your level of agreement by checking the appropriate rating.

Sergio Vañó Galván, MD, PhD, effectively:

* 15. Please rate your level of agreement by checking the appropriate rating.

The content presented: